CNS Pharmaceuticals, Inc. cotiza a 5.19 USD y tiene una capitalización bursátil de $8M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.38 | $-7.30 | $-10.15 | $-5.76 |
| Estimado | $-0.24 | $-5.37 | $-5.09 | $-6.63 |
| Sorpresa | -58.3% | -35.9% | -99.4% | +13.1% |
| Métrica | CNSP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -350.5% | -40.4% | -310.1% |
| ROA | -183.8% | -32.0% | -151.8% |
| Current Ratio | 1.98 | 2.84 | -0.86 |
| Debt / Equity | — | 0.28 | — |